The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Britigan, B. E.
Right arrow Articles by Krieg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Britigan, B. E.
Right arrow Articles by Krieg, A. M.
The Journal of Immunology, 2001, 167: 2921-2928.
Copyright © 2001 by The American Association of Immunologists

Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells1

Bradley E. Britigan2,*,{dagger},{ddagger}, Troy S. Lewis*, Mari Waldschmidt{dagger}, Michael L. McCormick*,{dagger},{ddagger} and Arthur M. Krieg*,{dagger},§,¶

* Research Service and Department of Internal Medicine, Veterans Affairs Medical Center, Iowa City, IA 52246; {dagger} Department of Internal Medicine, {ddagger} Free Radical Research Program, Department of Radiology, and § Immunology Program, University of Iowa College of Medicine, Iowa City, IA 52242; and Coley Pharmaceutical Group, Wellesley, MA 02481


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotides (ODN) containing these motifs, are potent stimuli for many host immunological responses. These CpG motifs may enhance host responses to bacterial infection and are being examined as immune activators for therapeutic applications in cancer, allergy/asthma, and infectious diseases. However, little attention has been given to processes that down-modulate this response. The iron-binding protein lactoferrin is present at mucosal surfaces and at sites of infection. Since lactoferrin is known to bind DNA, we tested the hypothesis that lactoferrin will bind CpG-containing ODN and modulate their biological activity. Physiological concentrations of lactoferrin (regardless of iron content) rapidly bound CpG ODN. The related iron-binding protein transferrin lacked this capacity. ODN binding by lactoferrin did not require the presence of CpG motifs and was calcium independent. The process was inhibited by high salt, and the highly cationic N-terminal sequence of lactoferrin (lactoferricin B) was equivalent to lactoferrin in its ODN-binding ability, suggesting that ODN binding by lactoferrin occurs via charge-charge interaction. Heparin and bacterial LPS, known to bind to the lactoferricin component of lactoferrin, also inhibited ODN binding. Lactoferrin and lactoferricin B, but not transferrin, inhibited CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-containing ODN may serve to modulate and terminate host response to these potent immunostimulatory molecules at mucosal surfaces and sites of bacterial infection.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Bacterial, but not eukaryotic, DNA contains a large number of unmethylated CpG dinucleotides (1). When these unmethylated CpGs are in a particular base context ("CpG motifs") they stimulate various innate and acquired immunological responses in murine and human systems (2). Among the effects of unmethylated CpG oligodeoxynucleotides (ODN)3 are: 1) enhancement of Ag-specific Th1 responses including enhanced macrophage and dendritic cell IL-12 production (3, 4, 5, 6, 7); 2) enhanced NK cell production of IFN-{gamma} (8); 3) activation of B cell proliferation and IL-6 and Ig secretion (7); 4) stimulation of protective immunity against intracellular pathogens (9, 10, 11, 12, 13, 14); 5) inhibition of allergen-and LPS-induced airway inflammation (15, 16, 17); 6) induction of direct airway inflammation (18); and 7) stimulation of immune responses to tumor Ags (19, 20). CpG-containing ODN have also been shown to be able to induce a systemic inflammatory response syndrome in animals that is analogous to that resulting from i.v. challenge with LPS (21).

These and other experimental data have suggested that immune stimulation by bacterial DNA may serve as an important signaling mechanism to activate protective immune responses to invasion by pathogenic bacteria (22). Given the potency of the response, the role of bacterial DNA and CpG ODN as potential vaccine adjuvants is being explored (3, 22). The biological effect of CpG ODN appears to involve binding and internalization of the molecule (23, 24) by a process that is mediated via a Toll-like receptor-dependent pathway (25, 26, 27) and perhaps formation of reactive oxygen species (28).

Although there has been much interest in the immunostimulatory effects of bacterial DNA, there has been relatively little attention paid to mechanisms whereby the host may limit and thereby help to regulate such responses. At many mucosal surfaces there is a normal resident microflora. Continued stimulation of the local immune system in response to the DNA of this microflora could be deleterious and it would be expected that a mechanism would have evolved to limit such events. Similarly, at a local site of bacterial infection, it would likely be beneficial to the host to have a means of terminating CpG-mediated stimulation of the immune system as the infection comes under control.

Lactoferrin is a highly cationic (isoelectric point (pI), 8.4–9.0) monomeric glycoprotein (76–80 kDa) that is found in high concentrations (1–10 mg/ml) at many mucosal surfaces and in milk (29, 30, 31). It is also a major constituent of neutrophil secondary (specific) granules (32, 33). It is secreted by local neutrophils and is present at high levels at sites of bacterial infection (34, 35). Lactoferrin contains two high-affinity ferric iron binding sites and is thought to function as host defense in part by sequestering iron from pathogenic microbes (36, 37). Lactoferrin is also thought to serve as an antioxidant since iron bound to the protein is unable to participate as a catalyst for the generation of the hydroxyl radical (38, 39, 40).

Lactoferrin has antimicrobial activity that is independent of its iron-binding activity (41, 42, 43). Lactoferrin binds to the outer membrane of Gram-negative bacteria, leading to alterations in bacteria membrane permeability barriers, which in turn causes microbial cell injury and death (41, 44). This latter activity has been linked to the proximal N terminus of the molecule, termed lactoferricin, which contains a large number of arginine residues. These are responsible for much of the cationic nature of the protein (42, 45). The related iron-binding protein transferrin, which lacks these arginines, has a pI of 5–5.5 (46).

The cationic N-terminal component of lactoferrin has also been shown to result in the ability of the molecule to bind a variety of biologically important, negatively charged molecules, via charge-charge interactions. These include LPS (47, 48, 49, 50, 51, 52, 53, 54), heparin, and heparan sulfates (47, 55, 56, 57) and DNA (47, 58, 59, 60). Binding of LPS to lactoferrin has been shown to modulate the bioactivity of LPS by altering how it interacts with target cells (49, 50, 52, 53). Most of the interest in the DNA-binding properties of lactoferrin has been on the interaction of the protein with eukaryotic DNA. Recently, there has been the suggestion that there may be a sequence specificity for binding of eukaryotic DNA to lactoferrin and that lactoferrin may play a role in transcriptional activation (61).

Given previous evidence that 1) lactoferrin can bind ssDNA; 2) interaction with another immunostimulatory molecule, LPS, is modified upon its binding to lactoferrin; and 3) lactoferrin is present in high concentrations at both mucosal surfaces and sites of acute bacterial infection, we hypothesized that lactoferrin will bind CpG-containing ODN and that this will lead to alterations in the biological activity of these ODN toward the immune system. Data reported herein support that hypothesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
32P-labeled ODN

The following ODN, which contained nondetectable levels of endotoxin, were provided by the Coley Pharmaceutical Group (Wellesley, MA): 2006, TCG TCG TTT TGT CGT TTT GTC GTT; 1818, GAG AAC GCT GGA CCT TCC AT; 1906, TCC ATG ACG TTC CTC TCC ATG ACG TTC CTC TCC ATG ACG TTC TTC CTC; and 1858, TCC AGT CTA CGC CTA GTT CT; 1888: TCC ATG ACG TTC CTA GTT CT.

The ODN of interest (200 ng) was incubated with T4 polynucleotide kinase (10 U) and [32P]ATP (30 µCi) in a volume of 40 µl for 30–60 min at 37°C. The solution was then centrifuged through a G-25 Sepharose column for 4 min at 2000 rpm at room temperature. The radiolabeled ODN was then harvested from the eluate, counted in a gamma counter, and then stored at -20°C until needed. For cellular uptake experiments, ODN with a 5' fluorescein modification (Operon Technology, Alameda, CA) were used.

EMSA

Binding of ODN to lactoferrin, transferrin, and lactoferricin B was assessed by EMSA. Lactoferrin (bovine and human) as well as transferrin were purchased from Sigma (St. Louis, MO). Lactoferricin B was kindly provided by the Morinaga Milk Industry (Zama City, Japan). 32P-labeled ODN was incubated alone or with the protein of interest for 2–5 min in H2O at room temperature. Samples were then subjected to native PAGE followed by overnight autoradiography (-80°C).

Ramos cell CD86 expression

The Ramos human B cell line (Burkitt lymphoma B cell line, ATCC CRL-1923) was maintained in RPMI 1640 supplemented with L-glutamine, penicillin, streptomycin, and HEPES. Cells were harvested and incubated in RPMI 1640 containing 10% FCS at a concentration of 1–2 x 106/ml. To these cell suspensions was then added ODN alone or ODN that had been preincubated with lactoferrin, lactoferricin B, or transferrin in H2O for 1 h at 37°C. After overnight incubation in 96-well flat-bottom plates, the cells were removed and assessed for CD86 expression by surface Ag staining using FITC-conjugated Ab to CD86 (2331 (FUN-1); purchased from BD PharMingen, San Diego, CA) in conjunction with FACS analysis (62). In some experiments, polyclonal antihuman IgM (Sigma) was substituted for the ODN as an alternative stimulus for Ramos cell CD86 expression.

Cellular uptake of CpG ODN

Ramos cells were incubated at 37°C with FITC-conjugated ODN in PBS, after initial incubation of the ODN for 30 min in H2O alone or H2O that contained desired concentrations of lactoferrin, transferrin, or lactoferricin B. After 3 h, the cells were washed and cell-associated FITC was determined by FACS (63). To correct for cell membrane binding, parallel cell samples were also incubated with ODN on ice for 30 min to prevent uptake.

Binding of lactoferrin to Ramos cells

Ramos cells were washed twice in HBSS and suspended at a concentration of 106/ml in 0.5 ml of HBSS at 4°C. To the cell suspension was added 5 µCi of 125I-labeled human apolactoferrin. After 30 min at 4°C, the cells were washed three times with cold HBSS and finally pelleted at 200 x g for 10 min. The tip of the centrifuge tube containing the cell pellet was cut from the tube using a clipper and placed into a tube which allowed determination of 125I-labeled human lactoferrin content by gamma counter. Each experiment included conditions in which 125I-labeled human apolactoferrin was added to HBSS which lacked cells and was processed in an analogous manner. This was done to control for nonspecific sticking of lactoferrin to the tubes (background). These background counts were subtracted from the cell-containing values to arrive at cell-specific lactoferrin binding.

Statistical analyses

Results obtained under different experimental conditions were compared by Student’s paired t test when independent variables were being assessed or by ANOVA when analyses of trends were being determined. For both types of analyses, results were considered to be significant at p <= 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Lactoferrin binds CpG ODN

Given that lactoferrin had previously been shown to bind to both ssDNA and dsDNA (47, 58, 59, 60), we examined the ability of lactoferrin to bind synthetic ODN with or without CpG motifs. Using 32P-labeled ODN in conjunction with EMSA analysis, human lactoferrin was found to bind such ODN in a concentration-dependent manner following a brief (2- to 5-min) exposure (Fig. 1Go). The binding was saturable, as it could be inhibited by the presence of a 100-fold concentration excess of unlabeled ODN (Fig. 1GoA). No difference in binding to lactoferrin was distinguishable among the CpG-and non-CpG-containing ODN examined (Fig. 1GoB), indicating that lactoferrin binding did not require the presence of the CpG motif. Neither was binding unique to human lactoferrin, as CpG ODN binding was also readily detectable using bovine lactoferrin (Fig. 1GoC).



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 1. Lactoferrin binds ODN. Human lactoferrin, at the indicated amounts, was incubated with 1 ng of 32P-labeled ODN in H2O for 2–5 min and then subjected to EMSA. Results are representative of three separate experiments. A, Lactoferrin binding to ODN; 1906 was readily detectable and was inhibited by a 100-fold excess of unlabeled ODN (far right lane *, containing 100 ng of unlabeled ODN). B, No difference in binding to lactoferrin was distinguishable between the CpG (1906)- and non-CpG (1858)-containing ODN. C, Both human and bovine lactoferrin were able to bind the ODN 1906. D, Both lactoferrin and iron-loaded (di-ferric) lactoferrin were able to bind the ODN 1906. Results shown are representative of at least three separate experiments.

 
Binding of iron to lactoferrin results in conformational changes in the molecule (64, 65, 66). However, comparison of ODN binding to apolactoferrin and iron-loaded forms of human lactoferrin revealed no differences in their ability to bind the CpG-containing ODN (Fig. 1GoD). In contrast, the related iron-binding protein transferrin was unable to bind the ODN under the same conditions (Fig. 2Go).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 2. Transferrin does not bind ODN. Five micrograms of human lactoferrin and transferrin were incubated with 1 ng of 32P-labeled ODN 1906 in H2O for 2–5 min and then subjected to EMSA to determine their relative ability to bind the ODN. Results are representative of three separate experiments.

 
Interestingly, in studies of lactoferrin binding to ODN 1906 at relatively low ratios of lactoferrin to ODN, we observed a single band that migrated well into the gel. As the concentration of lactoferrin increased, additional slower migrating bands appeared, and with further increases a single band was eventually seen with much slower migration into the gel (Fig. 1Go, A–C). Interestingly, this was not seen with the other ODN examined (Fig. 1GoB). ODN 1906 is nearly twice as long as the other ODN studied, and we hypothesize that this banding pattern reflects the ability of the 1906 ODN to bind several molecules of lactoferrin, resulting in the stepwise banding pattern on the gel.

Mechanism of CpG oligonucleotide binding to lactoferrin

The failure of the less cationic protein transferrin to bind the ODN, in conjunction with previous work by others (47, 58, 59, 60) examining the nature of lactoferrin-DNA interactions suggested that binding of CpG ODN occurred on the basis of a charge-charge interaction that likely involved the N-terminal portion of the lactoferrin molecule. To test this hypothesis, the effect of increasing salt concentration on the ability of lactoferrin to bind to CpG ODN was assessed. Consistent with a charge-charge-mediated interaction, high salt conditions (50 mM NaCl) resulted in a progressive decline in association of the ODN with lactoferrin (Fig. 3Go).



View larger version (74K):
[in this window]
[in a new window]
  		FIGURE 3. Lactoferrin binding of ODN is inhibited by high salt. Human lactoferrin (400 ng) was incubated with 0.5 ng of 32P-labeled ODN 1906 in either H2O or solutions containing various amounts of NaCl and subjected to EMSA. Results are representative of three separate experiments.

 
Previous work by others (47, 58) suggested that lactoferrin binding of eukaryotic DNA occurs at the same N-terminal portion of the lactoferrin molecule at which binding of other negatively charged biological molecules (e.g., LPS, heparin, and heparan sulfates) occurs (47, 48). In the present work, we found that both heparin and LPS inhibit binding of 32P-labeled ODN in a concentration-dependent manner (Figs. 4Go and 5Go).



View larger version (69K):
[in this window]
[in a new window]
  		FIGURE 4. Lactoferrin binding of ODN is inhibited by heparin. 32P-labeled ODN 1906 (1 ng) was incubated with 1 µg of lactoferrin in H2O in the presence of varying concentrations of heparan sulfate and subjected to EMSA. The presence of heparin interfered with the ability of lactoferrin to bind 32P-labeled ODN 1906 in a concentration-dependent manner, reflected as serial dilutions of heparin. Results are representative of three separate experiments.

 


View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 5. Lactoferrin binding of ODN is inhibited by LPS. 32P-labeled ODN 1906 (1 ng) was incubated with 1 µg of lactoferrin in the presence of increasing concentrations of Escherichia coli LPS (0.1–10 µg) and subjected to EMSA. The presence of LPS interfered with the ability of lactoferrin to bind 32P-labeled ODN 1906 in a concentration-dependent manner. Results are representative of three separate experiments.

 
These data are consistent with the primary binding site for the ODN being on the N-terminal portion of lactoferrin. To confirm this, we examined the ability of purified lactoferricin B, which is comprised of a short portion of the N-terminal sequence of bovine lactoferrin (42, 67), to bind 32P-labeled ODN. As shown in Fig. 6Go, lactoferricin B exhibited, on a molar basis, a similar ability to bind ODN.



View larger version (61K):
[in this window]
[in a new window]
  		FIGURE 6. Lactoferricin B binds ODN. Lactoferricin B, at the indicated concentrations, was incubated with 0.5–1 ng of 32P-labeled ODN 1906 in H2O for 2–5 min and then subjected to EMSA. Lactoferricin B binding to ODN 1906 was readily detectable and was inhibited by a 100-fold excess of unlabeled ODN (far right lane *, containing 100 ng of unlabeled ODN). Results are representative of three separate experiments.

 
Lactoferricin B contains a disulfide bond (67). This bond does not appear to be necessary for the ability of lactoferricin B to bind ODN as pretreatment of the molecule with the reducing agent DTT to break those bonds had no effect on subsequent binding of 32P-labeled ODN (data not shown).

Binding to lactoferrin alters the biological activity of CpG ODN

Previous work has shown that the binding of LPS to lactoferrin alters LPS biological activity (49, 50, 52, 53). Therefore, we hypothesized that binding of CpG ODN to lactoferrin or lactoferricin B would inhibit the immunomodulatory effects of that molecule. Alternatively, it was also possible that lactoferrin would enhance the CpG activity by increasing cellular uptake of the DNA. To distinguish between these two possibilities, we examined the effect of lactoferrin/lactoferricin B binding on the ability of CpG ODN to increase CD86 expression on the human B lymphocyte-derived Ramos cell line. This parameter was chosen because our previous experience had indicated that CD86 expression in this cell line is not modulated by LPS exposure (A. M. Krieg, unpublished observation), a response which if present could potentially confound data interpretation, given the ability of lactoferrin to bind LPS as well. As shown in Fig. 7Go, binding of the ODN to either lactoferrin or lactoferricin B significantly decreased the magnitude of resulting expression of CD86 on the cell surface. This inhibition could be overcome by increasing the concentration of the ODN in the assay (data not shown). In contrast, the related iron-binding protein transferrin was without effect. As a control for any possible generalized cytotoxic effects of lactoferrin, the effect of lactoferrin and lactoferricin B on the ability of polyclonal anti-IgM to enhance Ramos cell CD86 expression was examined. No effect was observed (Fig. 7Go), indicating that the effect of lactoferrin/lactoferricin B does not result from some general toxicity, but rather is specific for the ODN-induced response.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 7. Lactoferrin (LF) binding of CpG ODN decreases bioactivity. The Ramos human B cell line was incubated overnight with the CpG-containing ODN 1906 (1 µg/ml) alone or with the same amount of ODN that had been preincubated with human lactoferrin (0.5 mg/ml), transferrin (0.5 mg/ml), or lactoferricin B (30 µg/ml) for 1 h before it was added to the cell suspension. Following this incubation, the ability of the ODN to induce CD86 expression on the cell surface was assessed by FACS. Also shown are results in which the cells were exposed to an alternative stimulus of CD86 expression, anti-IgM (2 µg/ml), alone or in the presence of lactoferrin (0.5 mg/ml), as a control for possible nonspecific effects of lactoferrin on CD86 expression. Results are reported as mean ± SEM of the percentage of cells expressing CD86, representing three or more separate experiments. Results with the addition of lactoferrin or lactoferricin B to the ODN were significantly less than ODN alone at p < 0.05. No other results were significantly different from ODN alone.

 
Lactoferrin inhibits binding and internalization of CpG ODN

The biological effect of CpG ODN on cellular systems has been shown to require their binding and internalization by a mechanism that remains ill-defined (23, 24). Accordingly, we assessed the effect of binding of CpG ODN to lactoferrin on its uptake by Ramos cells by measuring the ability of the cells to take up FITC-conjugated ODN (expressed as mean fluorescence index (MFI) by FACS). Lactoferrin (0.5 µg/ml) significantly inhibited ODN uptake over 3 h at 37°C to 35 ± 6% of control (mean MFI ± SEM, n = 3, p < 0.05). In contrast, transferrin (0.5 µg/ml) was without effect: MFI was 83 ± 12% of control (n = 3, p > 0.05). The same concentration of lactoferrin also decreased ODN binding at 4°C by 50 ± 28% (n = 3, p < 0.05), reflecting an effect on surface binding as well as uptake over time. Transferrin again was without effect: MFI was 107 ± 32% of control (n = 3, p > 0.05).

These latter data suggested that the binding of the ODN to lactoferrin did not direct the ODN to a different surface receptor system, as has been described previously with monocytes and LPS (52). ODN also altered the interaction of lactoferrin with the Ramos cells. Binding of lactoferrin to Ramos cells was decreased by 71% when lactoferrin was preincubated with the ODN, decreasing from 150 ± 18 fmol lactoferrin/106 cells to 43 ± 8 fmol lactoferrin/106 cells (mean ± SEM, n = 4) when the lactoferrin was preincubated with ODN before addition to the cells (p < 0.02). Thus, it appears that the interaction of ODN and lactoferrin decreases the ability of both agents to bind to the Ramos cell surface.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The unmethylated CpG sequences that distinguish bacterial from eukaryotic DNA have been identified as potentially important signaling molecules whose recognition allows various aspects of the host immune system to be activated to respond to invading bacterial pathogens (1, 2). Both beneficial and deleterious consequences of such activation have been described (1, 2). Although much attention has been paid to the mechanism whereby CpG-containing ODN activate cellular immune responses in vitro and in vivo, there has been relatively little focus on the means whereby these responses are negatively modulated.

In the present work we show that lactoferrin, a protein present in high concentrations at mucosal surfaces, milk, and neutrophil-specific granules (29, 30, 31, 32, 33, 34, 68), readily binds CpG-containing DNA. Although lactoferrin plays a major role as an iron-binding protein, our work and results from other investigators (47) indicate that the iron status of the protein does not influence its DNA-binding activity. The ability of high salt and other negatively charged molecules to inhibit ODN binding indicates that this most likely occurs on the basis of charge-charge interactions. The fact that lactoferrin, but not the related iron-binding protein transferrin, was able to bind the ODN suggests that the high pI of lactoferrin relative to transferrin may be an important determinant of this activity. This is further supported by that fact that a small portion of the N-terminal sequence of lactoferrin that is responsible for much of the cationic nature of the molecule (lactoferricin) (42, 67) exhibited the same ability to bind ODN as the entire lactoferrin molecule.

This observation also has important implications for the potential for this interaction to occur in vivo where lactoferrin can be cleaved through protease activity to generate lactoferricin (42, 69, 70). Thus, even at sites of high protease activity, the ability of lactoferrin to bind DNA should remain intact. Furthermore, since the oxidation state of the sulfhydryl group of lactoferricin B does not appear to dramatically alter the ability of lactoferricin to bind ODN, this process should function both in highly oxidizing and reducing environments.

Previous work by others has shown that lactoferrin is capable of binding ssDNA and dsDNA (47, 58, 59, 60). Furmanski and colleague (61) indicated that there is a preferred sequence specificity for the binding of ODN by lactoferrin. These authors also reported that lactoferrin could be internalized and trafficked to cell nuclei where it could potentially serve as a regulator of gene transcription (61). Our data indicate that, at least in the case of DNA fragments that lactoferrin would initially encounter extracellularly, this process serves to inhibit rather than enhance intracellular localization.

Binding of LPS to the N-terminal sequence of lactoferrin has been shown to alter many of the proinflammatory effects of LPS (49, 50, 52, 53). We find that binding of CpG ODN to the same site of lactoferrin has a similar negative effect on the proinflammatory action of CpG sequences on human B cells. CpG-induced up-regulation of CD86 was blocked by lactoferrin as well as lactoferricin B. Since lactoferrin also decreased uptake of the ODN by these cells and since that uptake appears to be required for cellular activation (23, 24), it is likely that lactoferrin binding inhibits many additional effects of the CpG ODN as well. This effect was specific for lactoferrin relative to transferrin. Furthermore, as evidenced by the lack of effect of lactoferrin on the cellular response to polymeric anti-IgM, the inhibition appears to be specific for the ODN-mediated response and is not a generalized cytotoxic effect.

Lactoferrin binds to cells by at least two mechanisms: 1) high capacity low-affinity binding that may occur via charge-charge interactions with surface glycolipids or other molecules such as DNA (71, 72, 73, 74, 75, 76) and 2) lower capacity/higher affinity binding to one or more proteinaceous plasma membrane receptors (77, 78, 79, 80, 81, 82, 83). Lactoferrin has been reported to bind to B cells via interaction with DNA on the cell surface (74, 75) and it appears that B cell binding is mediated through the highly charged N-terminal sequence of lactoferrin (84). To our knowledge, no specific protein receptors for lactoferrin on the B cell surface have been reported. Thus, the biological response to CpG ODN bound to lactoferrin could be different in those cells possessing one or more high-affinity lactoferrin-binding mechanisms such as macrophages, hepatocytes, PHA-activated lymphocytes, and gastrointestinal epithelial cells (77, 78, 79, 80, 81, 82, 83). This requires further investigation.

Nevertheless, these data suggest that binding of bacterial DNA or DNA fragments could be a mechanism to modulate the proinflammatory effects of these compounds. Lactoferrin would seem to be ideally suited for this role as it is present at high concentrations at mucosal surfaces (1 mg/ml) and in human milk (10 mg/ml) (29, 30, 31). At these concentrations, which are far higher than those used in our experiments, it would be readily available to deal with bacterial DNA routinely present from those microorganisms colonizing these locations. This could serve to limit excessive immunostimulatory activity at mucosal surfaces colonized by large numbers of microbes, e.g., gut, without losing the ability to detect pathogens that have invaded into tissues past the anti-inflammatory layer of lactoferrin. Interestingly, CpG ODN are being explored as an immunoadjuvant for a variety of vaccines and as immunotherapeutic agents for cancer and allergic diseases (3, 22). The potential impact of lactoferrin in oral vaccine strategies using CpG ODN may need to be explored, particularly if they involve administration of CpG-containing vaccines to infants who are being breast-fed. Likewise, the delivery of CpG ODN to other mucosal surfaces such as the nasal cavity or lungs for allergy therapy (15) may require consideration of inhibitory effects of lactoferrin to achieve optimal therapeutic effects.

In addition, as a major component of neutrophil secondary granules. lactoferrin (32, 33) would be brought to the sites of bacterial infections as part of the initial host response to that infection and would be released into the extracellular environment through neutrophil degranulation (85). Thus, as the infection was being eradicated, the ratio of bacterial DNA and LPS to lactoferrin would gradually decrease, thereby decreasing the bioactivity of both proinflammatory molecules and helping to terminate CpG-mediated inflammatory responses.

Although the interaction of lactoferrin with DNA decreases under conditions of high local salt concentrations, this would not likely be encountered under most in vivo conditions. NaCl concentrations seldom exceed 150 mM in vivo. It was not until this salt concentration was exceeded that we found evidence for a decrease in lactoferrin-ODN interactions in vitro. Interestingly, although controversial (86, 87), the salt content of airway lining fluid of patients with cystic fibrosis has been reported to be elevated (88, 89). Under these conditions, certain antibacterial peptides function less effectively (88, 89). The cystic fibrosis airway is notable for the presence of chronic bacterial infections and an exaggerated host inflammatory response (90). It is interesting to speculate that a decrease in the ability of airway fluid lactoferrin to bind bacterial DNA, due to a higher than normal salt concentration of the cystic fibrosis airway, could contribute in some way to the overexuberant airway inflammatory response that marks this disease.

In summary, lactoferrin is able to bind CpG-containing ODN via a mechanism that appears to involve charge-charge interactions of the N-terminal sequence of the lactoferrin molecule. The lack of specificity of the binding for CpG motifs may actually serve to enhance the effectiveness of binding of potentially immunostimulatory DNA sequences in which the CpG motif may be initially buried within a complex DNA multimer and not be immediately accessible to lactoferrin. Binding to lactoferrin results in a loss of binding and internalization of the ODN by a human B cell line and a coincident inhibition of CD86 surface expression, a marker of the proinflammatory response to CpG ODN in these cells. Our results suggest that lactoferrin normally present at mucosal surfaces or brought to sites of infection by lactoferrin-containing neutrophils could serve as a means for the host to negatively modulate the widely described proinflammatory responses to bacterial DNA and CpG ODN-containing fragments of bacterial DNA.


   Acknowledgments
 
FACS services were provided by the Flow Cytometry Core of the University of Iowa Diabetes and Endocrinology Research Center (National Institutes of Health Grant DK25295).


   Footnotes
 
1 This work was supported by research grants from the Research Service of the Department of Veterans Affairs (to B.E.B., M.L.M., and A.M.K.), National Institutes of Health Awards RO1AI34954 (to B.E.B.) and RO1CA66570 (to A.M.K.), and a grant from the Coley Pharmaceutical Group (to A.M.K.). Back

2 Address correspondence and reprint requests to Dr. Bradley E. Britigan, Department of Internal Medicine, Division of Infectious Diseases, University of Iowa Hospitals and Clinics, SW54, GH, Iowa City, IA 52242. E-mail address: bradley-britigan{at}uiowa.edu Back

3 Abbreviations used in this paper: ODN, oligodeoxynucleotide; pI, isoelectric point; MFI, mean fluorescence index. Back

Received for publication April 2, 2001. Accepted for publication July 13, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Bird, A. P.. 1999. CpG-rich islands and the function of DNA methylation. Nature 321:209.
  2. Krieg, A. M., A.-K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546.[Medline]
  3. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, E. Raz. 1997. Immunostimulatory DNA sequences function as T-helper-1 promoting adjuvants. Nat. Med. 3:849.[Medline]
  4. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J. Exp. Med. 186:1623.[Abstract/Free Full Text]
  5. Hartmann, G., G. J. Weiner, A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305.[Abstract/Free Full Text]
  6. Halpern, M. D., R. J. Kurlander, D. S. Pisetsky. 1996. Bacterial DNA induces murine interferon-{gamma} production by stimulation of interleukin-12 and tumor necrosis factor-{alpha}. Cell. Immunol. 167:72.[Medline]
  7. Iho, S., T. Yamamoto, T. Takahashi, S. Yamamoto. 1999. Oligonucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-{gamma} production in vitro. J. Immunol. 163:3642.[Abstract/Free Full Text]
  8. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon {gamma}. Proc. Natl. Acad. Sci. USA 93:2879.[Abstract/Free Full Text]
  9. Elkins, K. L., T. R. Rhinehart-Jones, S. Stibitz, J. S. Conover, D. M. Klinman. 1999. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:2291.[Abstract/Free Full Text]
  10. Walker, P. S., T. Scharton-Kersten, A. M. Krieg, L. Love-Homan, E. D. Rowton, M. C. Udey, J. C. Vogel. 1999. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-{gamma}-dependent mechanisms. Proc. Natl. Acad. Sci. USA 96:6970.[Abstract/Free Full Text]
  11. Klinman, D. M., J. Conover, C. Coban. 1999. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67:5658.[Abstract/Free Full Text]
  12. Krieg, A. M., L. Love-Homan, A. K. Yi, J. T. Harty. 1998. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:2428.[Abstract/Free Full Text]
  13. Zimmerman, S., O. Egeter, S. Hausmann, G. B. Lipford, M. Rocken, H. Wagner, K. Heeg. 1998. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:3627.[Abstract/Free Full Text]
  14. Freidag, B. L., G. B. Melton, F. Collins, D. M. Klinman, A. Cheever, L. Stobie, W. Suen, R. A. Seder. 2000. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 68:2948.[Abstract/Free Full Text]
  15. Kline, J. D., T. J. Waldschmidt, T. R. Businga, J. E. Lemish, J. V. Weinstock, P. S. Thorne, A. M. Krieg. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:2555.[Abstract/Free Full Text]
  16. Schwartz, D. A., C. L. Wohlford-Lenane, T. J. Quinn, A. M. Krieg. 1999. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J. Immunol. 163:224.[Abstract/Free Full Text]
  17. Broide, D., J. Schwarze, H. Tighe, T. Gifford, M.-D. Nguyen, S. Malek, J. Van Uden, E. Martin-Orozco, E. W. Gelfand, E. Raz. 1998. Immunostimulatory DNA sequences inhibit IL-5 eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161:7054.[Abstract/Free Full Text]
  18. Schwartz, D. A., T. J. Quinn, P. S. Thorne, S. Sayeed, A.-K. Yi, A. M. Krieg. 1997. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest. 100:68.[Medline]
  19. Liu, H.-M., S. E. Newbrough, S. K. Bhatia, C. E. Dahle, A. M. Krieg, G. J. Weiner. 1998. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 92:3730.[Abstract/Free Full Text]
  20. Weiner, G. J., H. M. Liu, J. E. Wooldridge, C. E. Dahle, A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94:10833.[Abstract/Free Full Text]
  21. Cowdery, J. S., J. H. Chace, A. K. Yi, A. M. Krieg. 1996. Bacterial DNA induces NK cells to produce IFN-{gamma} in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570.[Abstract]
  22. Krieg, A. M.. 1999. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta 1489:107.[Medline]
  23. Hartmann, G., A. M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:944.[Abstract/Free Full Text]
  24. Häcker, H., H. Mischak, T. Miethke, S. Liptay, R. Schmid, T. Sparwasser, K. Heeg, G. B. Lipford, H. Wagner. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:6230.[Medline]
  25. Hemmi, H., O. Takeuchi, T. Kawal, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, S. Akira. 2000. A Toll-like receptor recognized bacterial DNA. Nature 408:740.[Medline]
  26. Schnare, M., A. C. Holt, K. Takeda, S. Akira, R. Medzhitov. 2000. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr. Biol. 10:1139.[Medline]
  27. Häcker, H., R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira, H. Wagner. 2000. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 192:595.[Abstract/Free Full Text]
  28. Yi, A.-K., R. Tuetken, T. Redford, M. Waldschmidt, J. Kirsch, A. M. Krieg. 1998. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160:4755.[Abstract/Free Full Text]
  29. Masson, P. L., J. F. Heremans, C. H. Dive. 1966. Studies on lactoferrin, an iron-binding protein common to many external secretions. Clin. Chim. Acta 14:735.
  30. Neville, M. C., K. Chatfield, L. Hansen, A. Lewis, J. Monks, J. Nuijens, M. Ollivier-Bousquet, F. Schanbacher, V. Sawicki, P. F. Zhang. 1998. Lactoferrin secretion into mouse milk: development of secretory activity, the localization of lactoferrin in the secretory pathway, and interactions of lactoferrin with milk iron. Adv. Exp. Med. Biol. 443:141.[Medline]
  31. Raphael, G. D., E. V. Jeney, J. N. Baraniuk, I. Kim, S. D. Meredith, M. A. Kaliner. 1989. Pathophysiology of rhinitis: lactoferrin and lysozyme in nasal secretions. J. Clin. Invest. 84:1528.
  32. Spitznagel, J. K., F. G. Dalldorf, M. S. Leffell, J. D. Folds, I. R. H. Welsh, H. H. Cooney, L. E. Martin. 1974. Character of azurophil and specific granules purified from human polymorphonuclear leukocytes. Lab. Investig. 30:774.[Medline]
  33. Baggiolini, M. C., C. deDuve, P. L. Masson, J. F. Heremans. 1970. Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J. Exp. Med. 131:559.[Abstract]
  34. Wright, D. G., J. I. Gallin. 1979. Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J. Immunol. 123:285.[Abstract/Free Full Text]
  35. Martins, C. A., M. G. Fonteles, L. J. Barrett, R. L. Guerrant. 1995. Correlation of lactoferrin with neutrophilic inflammation in body fluids. Clin. Diagn. Lab. Immunol. 2:763.[Abstract]
  36. Weinberg, E. D.. 1993. The development of awareness of iron-withholding defense. Perspect. Biol. Med. 36:215.[Medline]
  37. Finkelstein, R. A., C. V. Sciortino, M. A. McIntosh. 1983. Role of iron in microbe-host interactions. Rev. Infect. Dis. 5:5759.
  38. Britigan, B. E., G. M. Rosen, B. Y. Thompson, Y. Chai, M. S. Cohen. 1986. Stimulated neutrophils limit iron-catalyzed hydroxyl radical formation as detected by spin trapping techniques. J. Biol. Chem. 261:17026.[Abstract/Free Full Text]
  39. Winterbourn, C. C.. 1983. Lactoferrin-catalyzed hydroxyl radical production: additional requirements for a chelating agent. Biochem. J. 210:15.[Medline]
  40. Baldwin, D. A., E. R. Jenny, P. Aisen. 1984. The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J. Biol. Chem. 259:13391.[Abstract/Free Full Text]
  41. III Ellison, R. T., T. J. Giehl. 1991. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88:1080.
  42. Bellamy, W., M. Takase, H. Wakabayashi, K. Kawase, M. Tomita. 1992. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73:472.[Medline]
  43. Arnold, R. R., M. F. Cole, J. R. McGhee. 1977. A bactericidal effect for human lactoferrin. Science 197:263.[Abstract/Free Full Text]
  44. Bellamy, W. R., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, M. Tomita. 1993. Role of cell-binding in the antibacterial mechanism of lactoferricin B. J. Appl. Bacteriol. 75:478.[Medline]
  45. Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, M. Tomita. 1992. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta. 1121:130.[Medline]
  46. De Jong, G., J. P. Van Dijk, H. G. Van Eijk. 1990. The biology of transferrin. Clin. Chim. Acta 190:1.[Medline]
  47. Van Berkel, P. H. C., M. E. J. Geerts, H. A. Van Veen, M. Mericskay, H. A. De Boer, J. H. Nuijens. 1997. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328:145.
  48. Elass-Rochard, E., A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil, G. Spik. 1995. Lactoferrin-lipopolysaccharide interaction: involvement of the 28–34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem. J. 312:839.
  49. Cohen, M. S., J. Mao, G. T. Rasmussen, J. S. Serody, B. E. Britigan. 1992. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J. Infect. Dis. 166:1375.[Medline]
  50. Mattsby-Baltzer, I., A. Roseanu, C. Motas, J. Elverfors, I. Engberg, L. A. Hanson. 1996. Lactoferrin or a fragment thereof inhibits the endotoxin- induced interleukin-6 response in human monocytic cells. Pediatr. Res. 40:257.[Medline]
  51. Van Berkel, P. H. C., M. E. J. Geerts, H. A. Van Veen, P. M. Kooiman, F. R. Pieper, H. A. De Boer, J. H. Nuijens. 1995. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem. J. 312:107.
  52. Miyazawa, K., C. Mantel, L. Lu, D. C. Morrison, H. E. Broxmeyer. 1991. Lactoferrin-lipopolysaccharide interactions: Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J. Immunol. 146:723.[Abstract]
  53. Elass-Rochard, E., D. Legrand, V. Salmon, A. Roseanu, M. Trif, P. S. Tobias, J. Mazurier, G. Spik. 1998. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect. Immun. 66:486.[Abstract/Free Full Text]
  54. Appelmelk, B. J., Y.-Q. An, M. Geerts, B. G. Thijs, H. A. De Boer, D. M. MacLaren, J. De Graaff, J. H. Nuijens. 1994. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62:2628.[Abstract/Free Full Text]
  55. Zou, S., C. E. Magura, W. L. Hurley. 1992. Heparin-binding properties of lactoferrin and lysozyme. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 103B:889.
  56. Wu, H., R. L. Lundblad, F. C. Church. 1995. Neutralization of heparin activity by neutrophil lactoferrin. Blood 85:421.[Abstract/Free Full Text]
  57. Wu, H., D. M. Monroe, F. C. Church. 1995. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys. 317:85.[Medline]
  58. Kanyshkova, T. G., D. V. Semenov, V. N. Buneva, G. A. Nevinsky. 1999. Human milk lactoferrin binds two DNA molecules with different affinities. FEBS Lett. 451:235.[Medline]
  59. Hutchens, T. W., J. S. Magnuson, T.-T. Yip. 1989. Rapid purification of porcine colostral whey lactoferrin by affinity chromatography on ssDNA-agarose Characterization, amino acid composition and N-terminal amino acid sequence. Biochim. Biophys. Acta 999:323.[Medline]
  60. Hutchens, T. W., J. F. Henry, T.-T. Yip, D. L. Hachey, R. J. Schanler, K. J. Motil, C. Garza. 1991. Origin of intact lactoferrin and its DNA-binding fragments found in the urine of human milk-fed preterm infants: evaluation by stable isotopic enrichment. Pediatr. Res. 29:243.
  61. He, J., P. Furmanski. 1995. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721.[Medline]
  62. Hartmann, G., R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, et al 2000. Delineation of CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:1617.[Abstract/Free Full Text]
  63. Zhao, Q., Q. Matson, C. J. Herrara, E. Fisher, H. Yu, A. M. Krieg. 1993. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3:53.[Medline]
  64. Anderson, B. F., H. M. Baker, G. E. Norris, S. V. Rumball, E. N. Baker. 1990. Apolactoferrin structure demonstrates ligand-induced conformational changes in transferrins. Nature 344:784.[Medline]
  65. Chung, T. D. Y., K. N. Raymond. 1993. Lactoferrin: the role of conformational changes in its iron binding and release. J. Am. Chem. Soc. 115:6765.
  66. Grossmann, J. G., M. Neu, E. Pantos, F. J. Schwab, R. W. Evans, E. Townes-Andrews, P. F. Lindley, H. Appel, W.-G. Thies, S. S. Hasnain. 1992. X-ray solution scattering reveals conformational changes upon iron uptake in lactoferrin, serum and ovo-transferrins. J. Mol. Biol. 225:811.[Medline]
  67. Hwang, P. M., N. Zhou, X. Shan, C. H. Arrowsmith, H. J. Vogel. 1998. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288.[Medline]
  68. Kindås-Mügge, I., A. H. Hammerle, I. Fröhlich, C. Oismüller, M. Micksche, F. Trautinger. 1993. Granulocytes of critically ill patients spontaneously express the 72 kD heat shock protein. Circ. Shock 39:247.[Medline]
  69. Kuwata, H., T. T. Yip, M. Tomita, T. W. Hutchens. 1998. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim. Biophys. Acta Protein Struct. Mol. Enzymol. 1429:129.[Medline]
  70. Kuwata, H., T. T. Yip, C. L. Yip, M. Tomita, T. W. Hutchens. 1998. Direct detection and quantitative determination of bovine lactoferricin and lactoferrin fragments in human gastric contents by affinity mass spectrometry. Adv. Exp. Med. Biol. 443:23.[Medline]
  71. Roseanu, A., F. Chelu, M. Trif, C. Motas, J. H. Brock. 2000. Inhibition of binding of lactoferrin to the human promonocyte cell line THP-1 by heparin: the role of cell surface sulphated molecules. Biochim. Biophys. Acta 1475:35.[Medline]
  72. Damiens, E., I. El Yazidi, J. Mazurier, E. Elass-Rochard, I. Duthille, G. Spik, Y. Boilly-Marer. 1998. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur. J. Cell Biol. 77:344.[Medline]
  73. Donald, R., D. W. Ballard, J. Hawiger. 1995. Proteolytic processing of NF-{kappa}B/I{kappa}B in human monocytes. ATP-dependent induction by proinflammatory mediators. J. Biol. Chem. 270:9.[Abstract/Free Full Text]
  74. Bennett, R. M., J. Davis, S. Campbell, S. Portnoff. 1983. Lactoferrin binds to cell membrane DNA: association of surface DNA with an enriched population of B cells and monocytes. J. Clin. Invest. 71:611.
  75. Bennett, R. M., J. Davis. 1981. Lactoferrin binding to human peripheral blood cells: interaction with a B-enriched population of lymphocytes and a subpopulation of adherent mononuclear cells. J. Immunol. 127:1211.[Medline]
  76. Campbell, E. J.. 1982. Human leukocyte elastase, cathepsin G, and lactoferrin: family of neutrophil granule glycoproteins that bind to an alveolar macrophage receptor. Proc. Natl. Acad. Sci. USA 79:6941.[Abstract/Free Full Text]
  77. Mazurier, J., J. Montreuil, G. Spik. 1985. Visualization of lactotransferrin brush-border receptors by ligand-blotting. Biochim. Biophys. Acta 821:453.[Medline]
  78. Rochard, E., D. Legrand, J. Mazurier, J. Montreuil, G. Spik. 1989. The N-terminal domain I of human lactotransferrin binds specifically to phytohemagglutinin-stimulated peripheral blood human lymphocyte receptors. FEBS Lett. 255:201.[Medline]
  79. Bennatt, D. J., Y. Y. Ling, D. D. McAbee. 1997. Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. Biochemistry 36:8367.[Medline]
  80. McAbee, D. D., Y. Y. Ling, C. Stich. 1998. Iron loading of isolated rat hepatocytes inhibits asialoglycoprotein receptor dynamics and induces formation of rat hepatic leptin-1 (RHL-1) oligomers. Biochem. J. 331:719.
  81. Prieels, J.-P., S. V. Pizzo, L. R. Glasgow, J. C. Paulson, R. L. Hill. 1978. Hepatic receptor that specifically binds oligosaccharides containing fucosyl {alpha}1–3-N-acetylglucosamine linkages. Proc. Natl. Acad. Sci. USA 75:2215.[Abstract/Free Full Text]
  82. Kawakami, H., B. Lönnerdal. 1991. Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am. J. Physiol. 261:G841.[Abstract/Free Full Text]
  83. Willnow, T. E., J. L. Goldstein, K. Orth, M. S. Brown, J. Herz. 1992. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J. Biol. Chem. 267:26172.[Abstract/Free Full Text]
  84. Kawasaki, Y., K. Sato, H. Shinmoto, S. Dosako. 2000. Role of basic residues of human lactoferrin in the interaction with B lymphocytes. Biosci. Biotechnol. Biochem. 64:314.[Medline]
  85. Leffell, M. S., J. K. Spitznagel. 1975. Fate of human lactoferrin and myeloperoxidase in phagocytizing human neutrophils: effects of immunoglobulin G subclasses and immune complexes coated on latex beads. Infect. Immun. 12:813.[Abstract/Free Full Text]
  86. Knowles, M. R., J. M. Robinson, R. E. Wood, C. A. Pue, W. M. Mentz, G. C. Wagner, J. T. Gatsky, R. C. Boucher. 1997. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal disease-control subjects. J. Clin. Invest. 100:2588.[Medline]
  87. Matsui, H., B. R. Grubb, R. Tarran, S. H. Randell, J. T. Gatzy, C. W. Davis, R. C. Boucher. 1998. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005.[Medline]
  88. Smith, J. J., S. M. Travis, E. P. Greenberg, M. J. Welsh. 1996. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229.[Medline]
  89. Goldman, M. J., G. M. Anderson, E. D. Stolzenberg, U. P. Kari, M. Zasloff, J. M. Wilson. 1997. Human {beta}-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553.[Medline]
  90. Jr Fick, R. B.. 1993. Pathogenetic mechanisms in cystic fibrosis lung disease: a paradigm for inflammatory airways disease. J. Lab. Clin. Med. 121:632.[Medline]



This article has been cited by other articles:


Home page
 ThoraxHome page
P Geraghty, M P Rogan, C M Greene, M L Brantly, S J O'Neill, C C Taggart, and N G McElvaney
Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro
Thorax, July 1, 2008; 63(7): 621 - 626.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. B. Anderson, G. J. Cianciolo, M. N. Kennedy, and S. V. Pizzo
{alpha}2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism
J. Leukoc. Biol., February 1, 2008; 83(2): 381 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
D. M.E. Bowdish and R. E.W. Hancock
Anti-endotoxin properties of cationic host defence peptides and proteins
Innate Immunity, August 1, 2005; 11(4): 230 - 236.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
R. Schirmbeck, P. Riedl, R. Zurbriggen, S. Akira, and J. Reimann
Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells
J. Immunol., November 15, 2003; 171(10): 5198 - 5207.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
D. Caccavo, N. M. Pellegrino, M. Altamura, A. Rigon, L. Amati, A. Amoroso, and E. Jirillo
Review: Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application
Innate Immunity, December 1, 2002; 8(6): 403 - 417.
[Abstract] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Gursel, D. Verthelyi, I. Gursel, K. J. Ishii, and D. M. Klinman
Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide
J. Leukoc. Biol., May 1, 2002; 71(5): 813 - 820.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Britigan, B. E.
Right arrow Articles by Krieg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Britigan, B. E.
Right arrow Articles by Krieg, A. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS